MRK vs TRVI
MRK: Merck & Co. is a leading global biopharmaceutical firm dedicated to delivering life-saving vaccines and innovative therapeutic medicines for major disease areas. TRVI: Trevi Therapeutics is a clinical-stage biopharma company developing its lead product candidate, Haduvio, to treat challenging chronic pruritus and chronic cough conditions.
Side-by-side fundamentals
| Metric | MRK | TRVI | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $149.88 | $12.77 | |
| Market cap as of 2026-07-31 (share count; price 2026-10-21) | $369.8B | $1.8B | |
| P/E as of 2026-10-21 | 119.90 | n/a | |
| Net margin FY2025, SEC XBRL | +28.1% | n/a | |
| ROE FY2025, SEC XBRL | +34.7% | -23.3% | MRK higher |
| ROA FY2025, SEC XBRL | +13.3% | -22.1% | MRK higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.29 | n/a | |
| Revenue growth (YoY) FY2025, SEC XBRL | +1.3% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +3.1% | n/a | |
| Dividend yield as of 2026-09-03 | +2.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 19 | 0 | MRK higher |
| Beta as of 2026-09-03 | 0.29 | 0.50 | |
| 1-year return as of 2026-10-21 close | +71.1% | +19.9% | MRK higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.